As a major component and pivotal orchestrator of the tumor microenvironment, intratumoral cytotoxic CD8+ T‐cells have been shown to correlate with favorable clinical outcomes in CRC patients.[13, 14] These cells have the potential to recognize and destroy cancer cells during tumor immunosurveillance, and to determine cancer immunotherapeutic efficacy.[15, 16] However, the role of oncogenic KRAS in tumor‐infiltrating cytotoxic CD8+ T‐cell fate decisions has not been fully deciphered. This evidence concerns the gene CD8A and cancer.